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Introduction
Adenosine is a ubiquitous physiological regulator and
neuromodulator capable of ultiple physiological actions in
various systems[1].  Adenosine receptors are members of the
G-protein-coupled receptor superfamily, and comprise A1,
A2a, A2b, and A3 adenosine receptors, identified by conver-
gent data from molecular, biochemical, and pharmacological
studies[2].  A1R is widely expressed in the brain, adipose tissue,
the testis, and the spinal cord[3].  Via A1R, adenosine reduces
heart rate[4], glomerular filtration rate, and renin release in the
kidney[5], induces bronchoconstriction[6,7] and inhibits
Abstract
Aim: To study the modulating effect of adenosine deaminase (ADA) on yhe
adenosine A1 receptor (A1R) in HEK293 cells stably expressing the human A1R.
Methods: cDNA was amplified by RT-PCR using total RNA from human embryo
brain tissue as the template.  The PCR products were subcloned into the plasmid
pcDNA3 and cloned into the plasmid pcDNA3.1.  The cloned A1R cDNA was
sequenced and stably expressed in HEK293 cells.  The modulating effect of ad-
enosine deaminase on A1R was studied by using [3H]DPCPX binding assay and
an intracellular calcium assay.  Results: HEK293 cells stably expressing human
A1R were obtained.  Saturation studies showed that the KD value and Bmax value
of [3H]DPCPX were 1.6±0.2 nmol/L and 1.819±0.215 nmol/g of protein respectively,
in the absence of ecto-ADA respectively, and 1.3±0.2 nmol/L and 1.992±0.130
nmol/g of protein in the presence of ecto-ADA respectively, suggesting that the
KD value and Bmax value of [3H]DPCPX were unaffected by ecto-ADA.  In the case
of [3H]DPCPX competition curves obtained  from intact cells or membranes, A1R
agonist CCPA/[3H]DPCPX competition curve could be fitted well to a one-site
model in the absence of ecto-ADA and a two-site model in the presence of ecto-
ADA with a KH value of 0.74 (0.11–4.8) nmol/L (intact cells) or 1.8 (0.25–10) nmol/L
(membrane) and a KL value of 0.94 (0.62–1.41) µmol/L (intact cells) or 0.77 (0.29–
0.99) µmol/L (membrane). The KL value is not significantly different from the IC50
value of 0.84(0.57–1.23) µmol/L (intact cells) or 0.84 (0.63–1.12) µmol/L (membrane)
obtained in the absence of ecto-ADA.  Similar results were obtained from the
CPA/[3H]DPCPX competition curve in the absence or presence of ecto-ADA on
intact cells or membranes.  Intracellular calcium assay demonstrated that the EC50
value of CPA were 10 (5–29) nmol/L and 94 (38–229) nmol/L in the presence or
absence of ecto-ADA, respectively.  Conclusion: A1R stably expressed in the
HEK293 cells display a low affinity for agonists in the absence of ADA and high
and low affinities for agonists in the presence of ADA. The presence of ADA may
promote the signaling through the adenosine A1 receptor in HEK293 cells.
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lipolysis.  A1R can be coupled to different pertussis toxin-
sensitive G proteins[8–10], which mediate the inhibition of
adenylyl cyclase[11 ] and regulate Ca2+ and K+ channels and
inositol phosphate metabolism[12].  A1R present two different
affinities for agonists, which have classically been attributed
to a different coupling to heterotrimeric G proteins[13], coupled
receptor-G protein complexes display high affinity for A1R
agonists, whereas uncoupled receptors display low affinity[13,14].
Adenosine deaminase (ADA, E.C.3.5.4.4) is an enzyme
which catalyzes the hydrolytic deamination of adenosine to
inosine.  ADA is located both in the cytosol and on the cell
membrane.  Recent evidence suggest that ecto-ADA had
extra-enzymatic and co-stimulatory functional roles.  ADA
modulates ligand binding and signaling through A1R on
DDT1MF-2 cells, a smooth muscle cell line[15].  ADA seems
to be necessary for the high affinity binding of agonists to
A1R[16,17].  In the present study, the effect of ADA on the
ligand-mediated regulation of A1R in HEK293 cells stably
expressing human A1R has been studied.
Materials and methods
Materials  High glucose Dulbecco’s modified Eagle’s
medium (DMEM), fetal calf serum, G418, benzylpenicillin and
streptomycin were obtained from Gibco.  Restricted enzyme
(HindIII, EcoRI, XhoI), T4 DNA ligase, reverse transcriptase
enzyme and buffer were purchased from Promega (USA).
Pyrobest DNA polymerase and PCR  buffer were obtained
from TaKaRa (Dalian, China).  N6-cyclopentyladenosine
(CPA), 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), and 2-
Chloro-N6-cyclopentyladenosine (CCPA) were obtained from
RBI (Natick, MA, USA).  Adenosine deaminase was obtained
from Roche Biochemicals (Mannheim, Germany).  Fluo-3/AM,
p-(dipropylsulfamoyl)benzoic acid, pluronic F-127, HEPES,
Triton X-100, bovine serum albumin, leupeptin, pepstatin A,
aprotinin and PMSF were purchased from Sigma (USA).
[3H]DPCPX was purchased from Amersham (USA).  Plas-
mids pcDNA3, pcDNA3.1(+), and Lipofectamine2000 were pur-
chased from Invitrogen (USA).  Human embryo brain tissue
was donated by Huashan Hospital (Shanghai, China).  PCR
primers were synthesized by Shenyou (Shanghai, China).
Cloning of the human A1R cDNA   Human brain total
RNA was obtained from human embryo brain tissue.  The
total RNA was reverse-transcribed using oligo-dT18 as a
primer.  With the cDNA, PCR was carried out using the prim-
ers A1R-1SE and A1R-1AS (Table 1).  Gel-purified PCR prod-
uct was treated with EcoRI/XhoI and subcloned into the
EcoRI/XhoI site of the mammalian expression vector
pcDNA3.  With the subcloned A1R-pcDNA3 plasmid as
template, PCR was carried out using the primers A1R-2SE
and A1R-2AS (Table 2), which resulted in full length codon
sequence cDNA.  Gel-purified PCR product was treated with
HindIII/EcoRI and cloned into the HindIII/EcoRI site of the
mammalian expression vector pcDNA3.1(+).
Production of HEK293 cell lines stably expressing hu-
man A1R  HEK293 Cells were transfected with the A1R-
pcDNA3.1(+) expression vector, using the Lipofectamine2000
reagent.  Cells were treated with selection medium contain-
ing G418 (1 g/L) for 3 weeks to select stably transfected cells
displaying neomycin resistance.  Between 2 and 3 weeks in
the selection process, resistant cells began to appear.  They
were sought out by serial dilutions and allowed to grow from
single cells.  Receptor expression of single cell-derived colo-
nies was tested by radioligand binding assay.
Table 2.   Representative competition inhibition experiments of CCPA and CPA versus the A1R antagonist [3H]DPCPX in intact cells and membrane
preparations from A1R cells.  RH is expressed as a mean.  KH, and KL/IC50 are expressed as a mean with 95% confidence intervals.
                                                                       ADA                    RH (%)                          KH (nmol/L)                   KL/IC50 (µmol/L)
CCPA Intact cells –   0                                              0.84 (0.57–1.23)
+ 18 (3) 0.74 (0.11–4.8) 0.94 (0.62–1.41)
Membranes –   0 0.84 (0.63–1.12)
+ 25 (5.0) 1.8   (0.25–10) 0.77 (0.29–0.99)
CPA Intact cells –   0 1.3     (0.9–1.7)
+ 18 (3) 0.62   (0.1–4.9) 2.1     (1.3–3.3)
Membranes –   0 2.0     (1.5–2.5)
+ 32 (3) 0.47 (0.16–1.3) 2.7     (1.6–4.6)





A1R-2AS   GCGCGAATTCCTAGTCATCAGGCCTCTCTTCTGGG
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Cell culture  Human embryonic kidney (HEK293) cells
were cultured in DMEM containing streptomycin (100 mg/L),
benzylpenicillin (1000 kU/L) and fetal bovine serum (10%).
Cells were incubated at 37 °C in 5% CO2.  Stably transfected
HEK293 cell lines were cultured in DMEM high glucose me-
dium containing streptomycin (100 mg/L), benzylpenicillin
(1000 kU/L), G-418 (200 mg/L), and fetal bovine serum (10%).
Cells were incubated at 37 °C in 5% CO2.  For passaging, the
cells were detached from the cell culture flask by washing
with phosphate-buffered saline (PBS) and brief incubation
with trypsin (0.5 g/L)/EDTA (0.2 g/L).  The cells were pas-
saged every 3 d.
Membrane preparation  The A1R cells (HEK293 cells
stably expressing human A1R) were lifted from Petri dishes
with a cell scraper.  Harvested cells were washed twice with
ice-cold PBS and centrifuged at 420×g for 5 min at 4 °C.  The
cell pellet was resuspended with hyponic buffer (Tris-HCl 5
mmol/L, EDTA 2 mmol/L, pH 7.4, leupeptin 1 mg/ L, pepstatin
A 1 mg/L, aprotinin 1 mg/L, PMSF 1 mmol/ L) and sonicated
(18 s) three times on ice.  The homogenate was centrifuged
at 960×g for 10 min at 4 °C.  The precipitated nucleic fraction
was discarded and the supernatant was centrifuged at
40 000×g for 30 min at 4 °C.  The pellet was washed with 50
mmol/L Tris-HCl buffer (pH 7.4) and centrifuged again under
the same conditions.  Finally, the pellet was resuspended in
the same buffer, and protein concentration was determined
by using the BCA Kit (Pierce) as described previously[18].
[3H]DPCPX binding assays in intact cells and mem-
branes  Binding assays in intact cells were performed in a
reaction tube at a density of 2.0×105 cells per tube, using
[3H]DPCPX as a radioligand.  Cells were resuspended in 50
mmol/L Tris-HCl (pH 7.4) and treated with  ADA 65 nmol/L at
4 °C for 30 min[17].  After this treatment, cells were incubated
for 1 h at 37 °C with [3H]DPCPX 0.5 nmol/L for competition
assays.  Different concentrations of the A1R agonist CCPA
or CPA were used in the competition curves.
 Membranes (30–50 µg proteins) from A1R cells were re-
suspended in Tris-Cl 50 mmol/L (pH 7.4) and treated with
ADA 65 nmol/L at 4 °C for 30 min.  Saturation assays were
performed at different concentrations of [3H]DPCPX (0.05–
10 nmol/L) using unlabeled DPCPX (20 µmol/L) to obtain
nonspecific binding.  Competition curves were carried out
by using [3H]DPCPX 0.5 nmol/L and different concentra-
tions of A1R agonists CCPA or CPA.
After incubation for 1 h, the binding assays were stopped
by rapid filtration through Whatman GF/B filters, and the
filters were immediately washed three times with ice-cold
buffer.  Filters were then transferred to Eppendoff tubes, and
scintillation liquid was added to measure the radioactivity.
Intracellular Ca2+ measurements  Ca2+ fluorescence
measurements were performed using a NOVOstar plate
reader with a pipettor system (BMG labtechnologies,
Offenburg, Germany).  A1 cells were harvested with 0.05%
trypsin/0.02% EDTA and rinsed with high glucose DMEM
containing 10% fetal bovine serum, streptomycin 100 mg/L,
and benzylpenicillin 1000 kU/L.  Pelleted cells were resus-
pended in fresh medium and kept under 5% CO2 at 37 °C for
1 h and vortexed every 15 min.  After two washes with Krebs-
HEPES buffer, cells were loaded with Fluo-3/AM 5 µmol/L
for 30 min containing 1% pluronic F-127 and p-(dipropyl-
sulfamoyl)benzoic acid 2.5 mmol/L.  Then cells were rinsed 3
times with Krebs-HEPES buffer containing 0.5% bovine se-
rum albumin, the diluted, and evenly plated into 96-well
plates at a density of 1×104 cells/well.  Microplates were kept
at 37 °C for 15 min[19, 20].  Buffer alone or different concentra-
tions of CPA were then injected sequentially into separate
wells, and fluorescence intensity was measured at 520 nm
for 50 s at 0.2 s intervals.  The excitation wavelength was
485 nm.
      [Ca2+]i was calculated as follows: [Ca2+]i=Kd (F-Fmin)/(Fmax-
F).  Fmax refers to fluorescence intensity measured after
permeabilization of the cells with 1% Triton X-100.  Ten mmol/L
EDTA was added to chelate Ca2+ and minimum fluorescence
intensity was obtained (Fmin).  A Kd value of 324 nmol/L was
used for Fluo-3.
Data analysis  Experiments were performed in triplicate.
All data were expressed as mean±SD and data were analyzed
with the GraphPad Prism 4.0 program (GraphPad Software,
San Diego, CA, USA).  Student’s t-test was used for statisti-
cal analysis.
Results
Cloning of the human adenosine A1R cDNA  To obtain
the cDNA with the full length codon sequence of human
A1R, a reverse transcription reaction was carried out using
the total RNA extracted from human embryo brain tissue.
Using cDNA with full length codon sequence of A1R, a PCR
product (1332 bp) was obtained using primers described
previously.  The PCR product  subcloned into a pcDNA3
plasmid and cDNA (981 bp) containing the  full A1R codon
sequence was obtained using this subcloned vector as a
template.  The cDNA was then cloned into the mammalian
expression vector pcDNA3.1.  Sequence analysis demon-
strated that the sequence of the constructed A1R-pcDNA3.1
expression vector was identical to that of human A1R cDNA
in the gene bank.
Selection of cell clones  Colonies of the selected stable
Http://www.chinaphar.com Sun WC et al
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integrants were initially analyzed for human A1R expression
by using a receptor binding assay using [3H]DPCPX.  From
the transfected HEK293 cell clones, one cell line was ob-
tained with specific [3H]DPCPX binding.
Saturation experiments with the adenosine A1 recep-
tor antagonist [3H]DPCPX  As Figure 1 shown, no signifi-
cant difference was found between the A1R cells in the ab-
sence and presence of ADA with respect to the Bmax and KD
values for the A1R binding sites labeled with [3H]DPCPX.
The Bmax values for the A1R cells were 1.819±0.215 and
1.992±0.130 nmol/g of protein (n=3) in the absence and
presence of ADA, respectively.  The KD values for the
A1R cells were 1.6±0.2 and 1.3±0.2 nmol/L (n=3) in the
absence and presence of ADA, respectively.  The non-
specific binding was <5% of the total binding.
Competition experiments of A1R agonist CCPA or CPA
versus the A1R antagonist [3H]DPCPX  Competition experi-
ments with CCPA versus the A1R antagonist [3H]DPCPX in
intact A1R cells or membrane preparations from A1R cells
incubated previously with ADA showed a significantly bet-
ter fit with the 2 binding sites model than that with the 1
binding site model (F test, P<0.05).  Similar KH and KL values
were obtained in intact cells or membrane preparations from
A1R cells incubated previously with ADA, and the propor-
tions of the A1R in the high affinity state (RH values) were
18%±3% and 20%±5% , respectively (Figure 2 and Table 2).
In intact A1R cells or membrane preparations from A1R cells
in the absence of ADA, a significant better fit for one bind-
ing site (RH =0) was obtained, with the IC50 values very simi-
lar to the KL value obtained in intact cells or membrane prepa-
rations previously treated with ADA.  Similar results were
obtained from competition experiments with CPA versus the
adenosine A1R antagonist [3H]DPCPX in intact A1R cells or
membrane preparations from A1 cells in the absence of ADA
(Figure 3, Table 2).
Effects of A1R agonist CPA on intracellular calcium level
in the presence or absence of ADA  An increase in intracellu-
lar Ca2+ appears to be a universal second messenger signal
for a majority of recombinant GPCRs[20].  A1R agonists evoked
a concentration-dependent and reproducible Ca2+ signal at
A1R[22].  To assess the effect of the presence of ADA on A1R
signal transduction, we performed an intracellular calcium
assay.  A significant difference was found between the A1R
cells in the absence and presence of ADA  with respect to
the EC50 values of A1R agonist CPA.  A1R agonist CPA in-
duced an intracellular [Ca2+] increase.  The EC50 values for
the A1R cells in the absence and presence of ADA were 94
(38–229) and 10 (5–29) nmol/L, respectively.  CPA appears
more potent at the A1 cells in the presence of ADA compared
with the A1R cells in the absence of ADA (Figure 4).
Figure 1.  Saturation curve of [3H]DPCPX binding to adenosine A1R in plasma membrane isolated from A1R cells untreated (A, B) and treated
(C, D) with ADA.  Binding assays were performed as described in Methods, using A1R antagonist [3H]DPCPX as radioligand in a concentration
range from 0.05 to 10 nmol/L.  A and C: Saturation curve of [3H]DPCPX binding to adenosine A1 receptors.  B and D: Scatchard plot of these
data and analysis gave the KD and Bmax values indicated in Results.  Data are mean±SD and were obtained from three independent experiments
performed in triplicate.
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Discussion
Recently, several evidences demonstrated that cell-sur-
face ADA interacted with A1 receptors in brain cortex and
DDT1MF-2 cells and that the enzyme was able to modulate
ligand binding and signaling through A1R[16,21–23].  By immu-
noprecipitation and affinity chromatography, it was found
that ADA and A1R interacted in pig brain cortical membranes.
By means of this interaction ADA led to the appearance of
the high-affinity site of the receptor.  Thus, it seems that
ADA is necessary for coupling A1R to heterotrimeric G pro-
teins[16].  In Chinese hamster ovary (CHO) cells, stably trans-
fected with the human adenosine A1R, it was found that in
the presence of ADA, the [3H]DPCPX/cyclohexyladenoine
competition curve could be analysed by a two-site model
with 93% of the sites having high affinity and the remainder
having low affinity.  In the absence of ADA, the [3H]DPCPX/
cyclohexyladenosine competition curve was well described
by a two-site model.  Under these conditions, 70% of the
binding of [3H]DPCPX was associated with a high-affinity
site with the remaining sites having low affinity.  Thus there
is a clear difference in the potency of cyclohexyladenosine
Figure 2.  Representative competitive inhibition curve of A1R ago-
nist CCPA versus the A1R antagonist [3H]DPCPX in intact cells (A)
and membrane preparations (B) from A1R cells untreated and treated
with ADA.  Competition assays were done at 0.5 nmol/L [3H]DPCPX
and increasing concentrations of CCPA.  IC50 values are means (95%
confidence intervals) obtained from three independent experiments
performed in triplicate.
Figure 3.  Representative competitive inhibition curve of A1R ago-
nist CPA versus the A1R antagonist [3H]DPCPX in intact cells (A)
and membrane preparations (B) from A1R cells untreated and treated
with ADA.  Competition assays were done at 0.5 nmol/L [3H]DPCPX
and increasing concentrations of CPA.  IC50 values are means (95%
confidence intervals) obtained from three independent experiments
performed in triplicate.
Figure 4 .  Concentra tion-response curves for the effect of A1R
agonist CPA on intracellular [Ca2+] in A1R cells untreated and treated
with ADA.  Mean±SD.  n=3.  EC50 values is mean (95% confidence
intervals) obtained from three independent experiments performed
in triplicate.
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at the high-affinity state[24].  In the present study, human
adenosine A1R were cloned and stably expressed in the
HEK293 cells and the effects of ecto-ADA on adenosine
A1R were studied.  By using competitive inhibition assay of
adenosine A1R agonists CCPA or CPA against [3H]DPCPX,
we found that A1R displayed two different affinities for ago-
nists in the presence of ADA.  However, A1R only displayed
a low affinity for agonists in the absence of ADA, suggest-
ing that most of the binding of [3H]DPCPX was associated
with the low-affinity site under these conditions and that the
interaction of ADA with A1 adenosine receptors led to the
appearance of the high-affinity site of the receptor.
To further demonstrate possible interaction between A1R
and ADA, intracellular calcium assay was carried out in the
present studies.  The results demonstrated that the EC50 value
of CPA for inducing increase of intracellular calcium level
was lower in the presence of ADA than that in the absence of
ADA, suggesting that the presence of ADA may promote
signaling through A1 receptors in the stably transfected
HEK293 cells.  Our results further support the notion that
ADA may promote the signaling through A1 receptors.
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